A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers

Trial Profile

A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2014

At a glance

  • Drugs MK 2206 (Primary) ; Selumetinib (Primary)
  • Indications Cholangiocarcinoma; Gallbladder cancer; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Sep 2014 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 18 Jun 2013 Planned end date (Sep 2014) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top